Share
Multiple myeloma (a type of blood cancer) patients live much longer today than in the past, thanks to new targeted anti-myeloma drugs, but ultimately most develop resistance to the medications, and in some the disease is resistant to therapy from the start. Weizmann Institute of Science researchers, in collaboration with physicians from
Tel Aviv Sourasky Medical Center (TASMC), have made use of extremely sensitive genomic technology to reveal genetic pathways that characterize some of the more resistant cases of multiple myeloma.
Nature Medicine, may lead to a more informed, personalized treatment for these patients, and it paves the way to using this new technology for discovering additional disease targets in other cancers.